SoliPharma, founded by Dr. Sheng Xiaoxia in 2010, is a pioneer in innovative drug delivery for skin health. We develop cutting-edge treatments to address the unmet needs of dermatology.

SoliPharma excels in solid-state research and complex formulation. As a leading CDMO, we provide comprehensive development and manufacturing services to global clients. By harnessing our expertise, we maximize the potential of your innovative drug molecules.

SoliPharma has been a trusted CDMO partner for over 15 years, serving 800+ global clients. We've successfully completed pre-formulation and formulation for 2000+ compounds at different clinical stages and annually generated 200K+ analytical testing reports, empowering our clients to navigate IND/NDA/ANDA submissions with confidence to both China NMPA and US FDA.

SoliPharma's innovative technology platform, a fusion of crystal engineering and polymer materials, has revolutionized topical and transdermal delivery. This breakthrough has enabled us to develop a diverse pipeline of topical products, addressing a wide range of dermatological conditions. Our portfolio includes 505(b)2 drugs, complex generics, US OTC products, and skincare solutions. With over 30 pharmaceutical products in development pipeline, SoliPharma is dedicated to addressing unmet needs in dermatology.

A global leader in dermatology, rooted in China. SoliPharma delivers high-quality products, a strong brand, and exceptional technical services. With a strong foundation in China, we are expanding our reach worldwide.